NEW: A compound from the Hergenrother/Shapiro collaboration has been licensed and is advancing toward treatment of breast cancer.

Unprecedented Compound Takes a Step Toward Breast Cancer Clinical Trials

Estrogen receptor-positive breast cancer is the most common form of breast cancer, affecting approximately 75% of breast cancer patients. In advanced and metastatic form, it is lethal, claiming the lives of nearly 350,000 individuals annually. Presently, no drug is able to eradicate these advanced tumors.

Cancer Center at Illinois (CCIL) researchers Paul Hergenrother and David Shapiro are working to change that with the anticancer compound developed in their collaborative labs and now licensed for pre-clinical development.

Read more: